tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immunovant resumed with a Neutral at Goldman Sachs

Goldman Sachs resumed coverage of Immunovant (IMVT) with a Neutral rating and $18 price target The firm sees limited downside but also a challenging regulatory backdrop for the company.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1